Beleggen.nl Markt MonitorMarkt Monitor

Amerikaanse aandelen Terug naar discussie overzicht

Hemispherx BioPharma, Inc (Public, AMEX:HEB)

13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 »» | Laatste | Omlaag ↓
  1. [verwijderd] 26 maart 2012 15:54
    quote:

    bertje007 schreef op 30 januari 2012 23:16:

    We hebben de 0.50 aangetikt maar zijn er helaas niet doorgegaan, hopelijk morgen meer geluk.

    Tijd voor nog enkele persberichtjes.
    Hemispherx BioPharma, Inc. Comm (HEB)
    -AMEX

    0.4002 Up 0.0314(+8.51%)

    Hemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)

    finance.yahoo.com/news/hemispherx-pub...

    Skip
  2. p/o 23 juli 2012 18:24
    En volledig terug kwijt.

    Had hoop ze eindelijk te kunnen verkopen, maar we zullen er maar terug enkele maanden bijdoen zeker.
  3. p/o 23 juli 2012 21:53
    Vorige week dinsdag nog 0.45 nu
    0.3223 -0.0377(-10.47%)
    Is echt een aandeel geworden om ritjes te maken, met blijven zitten zul je hier niks verdienen.
  4. [verwijderd] 14 augustus 2012 23:25
    Hemispherx BioPharma, Inc (NYSEAMEX:HEB) shares climbed 9.12% to $0.480 in the early hour after the company announced that it filed on July 31, 2012 with the U.S. Food and Drug Administration complete response to the FDA's November 25, 2009 Complete Response Letter in support of Ampligen's New Drug Application for Chronic Fatigue Syndrome (CFS). On August 10, 2012, the FDA acknowledged in writing receipt of the Company's August 1, 2012, response stating, "It considers this a complete, class 2 response to November 25, 2009, action letter. Therefore, the user fee goal date is February 2, 2013.

    He Bert, blijven zitten, wordt het leuk.. Of eruit.. heb de neiging om lekker te blijven zitten ..maybe a spike..

  5. p/o 15 augustus 2012 17:49
    Sta om te verkopen aan 0.56, nadat we gisteren boven de 0.51 gingen had ik al terug hoop, maar na de 0.43 van daarstraks zal ik terug wat langer mogen wachten.

    Ik vermoed dat ze van de stijgingen gebruik maken om vers geld op te halen. (waardoor we dan telkens terug die dalingen van 15 - 20% krijgen.
  6. p/o 23 augustus 2012 17:01
    Al een stuk verkocht aan 0.537 (staat nu 0.5491) dus gaan ze nu waarschijnlijk recht naar de 1 ;-)
  7. p/o 23 augustus 2012 17:47
    ik kan al beginnen spijt krijgen dat ik mijn 0.56 heb aangepast (0.5626)
  8. p/o 24 augustus 2012 17:48
    En toch vertrouw ik het ook niet. (en ik zeg dit als aandeelhouder)

    Ze willen nog altijd geld op halen door massaal aandelen ter beschikking te stellen.

    On July 23, 2012, Hemispherx Biopharma, Inc. (the “Company”) entered into an Equity Distribution Agreement with Maxim Group
    LLC (the “Agreement”) to create an at-the-market equity program under which it may sell up to $75,000,000 worth of shares of its common
    stock (the “Shares”) from time to time through Maxim Group LLC, as sales agent (the “Agent”). Under the Agreement, the Agent will be
    entitled to a commission at a fixed commission rate of 4.0% of the gross sales price of Shares sold under the Agreement, up to aggregate gross
    proceeds of $10,000,000, and, thereafter, at a fixed commission rate of 3.0% of the gross sales price of Shares sold under the Agreement.
  9. johnny baboa 28 augustus 2012 19:14

    DEZE BEDOEL IK

    Bandito1983 schreef op 14 dec 2010 om 15:30:

    [...]

    November 2010 - If you purchased or otherwise acquired Hemispherx Biopharma, Inc. (“Hemispherx”) common stock from February 18, 2009 through and including December 1, 2009, then you could receive a payment from the proposed Settlement of a securities class action lawsuit pending in Court.

    A Settlement has been proposed that will provide a settlement fund of $3.6 million in cash, plus interest (the “Settlement Fund”), to settle claims of investors who suffered damages from buying or otherwise acquiring Hemispherx common stock from February 18, 2009 through and including December 1, 2009. A hearing will be held on January 20, 2011 in Philadelphia, PA, to determine (1) whether the proposed Settlement (the "Settlement") of the above-captioned action ("Action") for $3,600,000 should be approved by the Court as fair, reasonable, and adequate; (2) whether the motion of Co-Lead Counsel for an award of attorneys' fees and reimbursement of expenses should be approved; and (3) whether the Action should be dismissed with prejudice.

    November 2009 - An investor in Hemispherx BioPharma, Inc (Public, AMEX:HEB) has filed a lawsuit in the United States District Court for the Eastern District of Pennsylvania on behalf of those who purchased the securities of Hemispherx Biopharma, Inc. (AMEX: HEB) between February 18, 2009 and October 30, 2009, over alleged violations of Federal Securities Laws.

    According to the complaint the plaintiff alleges that the defendants violated the federal securities laws by misleading investors regarding the status of Hemispherx's New Drug Application ("NDA") for its drug Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, so the lawsuit, defendants failed to disclose that the FDA had requested several reports from Hemispherx Biopharma before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. Then, on November 2, 2009, when Hemispherx Biopharma disclosed this information, the price of Hemispherx Biopharma securities (HEB) fell 20% to close at $1.13 on the next trading day, November 3, 2009.

    Hemispherx BioPharma, Inc said in a press release that it believes that the lawsuit is without merit and the fraud claim is irrefutably false.

    Hemispherx Biopharma, Inc., located inPhiladelphia, PA, is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s products include Ampligen and Alferon N and Injection. Hemispherx BioPharma, Inc reported in 2007 Total Revenue of $1.06million and in 2008 Total Revenue of $0.27million. Shares of Hemispherx BioPharma, Inc traded recently at $1.08 per share

    shareholdersfoundation.com/case/hemis...

    Deze bedoel ik , ik heb een cheque gekregen van 528.56 dollar [5000
    aandelen toen in mijn bezit]

13.337 Posts
Pagina: «« 1 ... 662 663 664 665 666 667 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 467 7.752
AB InBev 3 5.624
Abionyx Pharma 2 29
Ablynx 43 13.357
ABN AMRO 1.583 55.291
ABO-Group 1 28
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 268
Accsys Technologies 24 12.498
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 204
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 15 18.914
Aedifica 3 1.036
Aegon 3.259 324.796
AFC Ajax 538 7.132
Affimed NV 2 6.358
ageas 5.845 109.981
Agfa-Gevaert 15 2.161
Ahold 3.542 74.581
Air France - KLM 1.026 35.975
AIRBUS 1 15
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 469 13.315
Alfen 18 29.222
Allfunds Group 4 1.754
Almunda Professionals (vh Novisource) 651 4.282
Alpha Pro Tech 1 17
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.487 114.840
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.862 252.706
AMG 973 140.622
AMS 3 73
Amsterdam Commodities 307 6.908
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 581
Antonov 22.632 153.607
Aperam 93 15.656
Apollo Alternative Assets 1 17
Apple 5 409
Arcadis 254 9.834
Arcelor Mittal 2.044 322.239
Archos 1 1
Arcona Property Fund 1 305
arGEN-X 18 11.837
Aroundtown SA 1 251
Arrowhead Research 5 9.957
Ascencio 1 38
ASIT biotech 2 697
ASMI 4.109 40.859
ASML 1.769 129.948
ASR Nederland 21 4.611
ATAI Life Sciences 1 7
Atenor Group 1 556
Athlon Group 121 176
Atos 4 3.526
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 35 17.821
Axsome Therapeutics 1 177
Azelis Group 2 15
Azelis Group NV 2 167
Azerion 7 3.837